161 related articles for article (PubMed ID: 8758473)
41. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
42. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.
Segreti J; Kessler HA; Kapell KS; Trenholme GM
Antimicrob Agents Chemother; 1987 Jan; 31(1):100-1. PubMed ID: 2952061
[TBL] [Abstract][Full Text] [Related]
43. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.
Somani J; Bhullar VB; Workowski KA; Farshy CE; Black CM
J Infect Dis; 2000 Apr; 181(4):1421-7. PubMed ID: 10762573
[TBL] [Abstract][Full Text] [Related]
44. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.
Welsh LE; Gaydos CA; Quinn TC
Antimicrob Agents Chemother; 1992 Feb; 36(2):291-4. PubMed ID: 1318677
[TBL] [Abstract][Full Text] [Related]
45. [Effect of ofloxacin, pefloxacin, and tobramycin on the hydrophobicity of Klebsiella pneumoniae].
Hostacká A
Epidemiol Mikrobiol Imunol; 1999 Feb; 48(1):28-30. PubMed ID: 11038674
[TBL] [Abstract][Full Text] [Related]
46. Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo.
Johannisson G; Sernryd A; Lycke E
Sex Transm Dis; 1979; 6(2):50-7. PubMed ID: 494040
[TBL] [Abstract][Full Text] [Related]
47. [In vitro inhibition of Chlamydia trachomatis growth by liposome-encapsulated cyclines].
Sangaré L; Morisset R; Ravaoarinoro M
Pathol Biol (Paris); 2001 Feb; 49(1):53-6. PubMed ID: 11265224
[TBL] [Abstract][Full Text] [Related]
48. [Evaluation of in vivo activity of antibiotics against Chlamydia trachomatis in mice].
Bannai H; Miyazawa H; Ashihara Y
Kansenshogaku Zasshi; 1988 Mar; 62(3):246-52. PubMed ID: 3147305
[No Abstract] [Full Text] [Related]
49. Determination of the inhibitory concentration 50% (IC50) of four selected drugs (chlortetracycline, doxycycline, enrofloxacin and difloxacin) that reduce in vitro the multiplication of Chlamydophila psittaci.
Failing K; Theis P; Kaleta EF
Dtsch Tierarztl Wochenschr; 2006 Nov; 113(11):412-7. PubMed ID: 17147151
[TBL] [Abstract][Full Text] [Related]
50. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France).
Lefèvre JC; Lépargneur JP
Sex Transm Dis; 1998 Aug; 25(7):350-2. PubMed ID: 9713914
[TBL] [Abstract][Full Text] [Related]
51. In-vitro activity of fleroxacin against Chlamydia trachomatis.
Steele-Mortimer O; Meier-Ewert H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.
Bailey JM; Heppleston C; Richmond SJ
Antimicrob Agents Chemother; 1984 Jul; 26(1):13-6. PubMed ID: 6383207
[TBL] [Abstract][Full Text] [Related]
53. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis.
Skerk V; Krhen I; Lisić M; Begovac J; Roglić S; Skerk V; Sternak SL; Banaszak A; Strugar-Suica J; Vuković J
Int J Antimicrob Agents; 2004 Aug; 24(2):188-91. PubMed ID: 15288321
[TBL] [Abstract][Full Text] [Related]
54. Chlamydia trachomatis: in vitro susceptibility to antibiotics singly and in combination.
Christensen JJ; Holten-Andersen W; Nielsen PB
Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):329-32. PubMed ID: 3788573
[TBL] [Abstract][Full Text] [Related]
55. In-vitro activity of ofloxacin against Chlamydia trachomatis.
Sambri V; Rumpianesi F; Xerri L; Cevenini R
J Chemother; 1989 Aug; 1(4):231-2. PubMed ID: 2809689
[TBL] [Abstract][Full Text] [Related]
56. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro.
Dreses-Werringloer U; Padubrin I; Jürgens-Saathoff B; Hudson AP; Zeidler H; Köhler L
Antimicrob Agents Chemother; 2000 Dec; 44(12):3288-97. PubMed ID: 11083629
[TBL] [Abstract][Full Text] [Related]
57. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
Roblin PM; Hammerschlag MR
Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
[TBL] [Abstract][Full Text] [Related]
58. Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.
Webberley JM; Matthews RS; Andrews JM; Wise R
Eur J Clin Microbiol; 1987 Oct; 6(5):587-9. PubMed ID: 2449348
[TBL] [Abstract][Full Text] [Related]
59. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
Hammerschlag MR; Qumei KK; Roblin PM
Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
[TBL] [Abstract][Full Text] [Related]
60. Growth cycle-dependent pharmacodynamics of antichlamydial drugs.
Siewert K; Rupp J; Klinger M; Solbach W; Gieffers J
Antimicrob Agents Chemother; 2005 May; 49(5):1852-6. PubMed ID: 15855506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
